½ÃÀ庸°í¼­
»óǰÄÚµå
1600662

ÇÇÀÓ¾à ½ÃÀå : Á¦Ç°, ¼ºº°, ¹æ¹ý, À¯Å뺰 - ¼¼°è ¿¹Ãø(2025-2030³â)

Contraceptive Market by Product (Devices, Drugs), Gender (Female Contraceptive, Male Contraceptive), Method, Distribution - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 195 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ÇÇÀÓ¾à ½ÃÀåÀÇ 2023³â ±Ô¸ð´Â 484¾ï 3,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 548¾ï 7,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 13.82%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿© 2030³â¿¡´Â 1,198¾ï 9,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.

ÇÇÀÓ¾à ½ÃÀå¿¡´Â ÀÓ½ÅÀ» ¿¹¹æÇϰí, »ý½Ä °Ç°­À» °ü¸®Çϸç, ¼ºº´¿¡ ´ëóÇϱâ À§ÇÑ ´Ù¾çÇÑ Á¦Ç°°ú ¼­ºñ½º°¡ Æ÷ÇԵ˴ϴÙ. ¿©±â¿¡´Â ÇÇÀÓ¾à, ÇÇÀÓ¾à°ú °°Àº È£¸£¸ó ÇÇÀÓ¹ý, Äܵ¼, ´ÙÀ̾îÇÁ·¥°ú °°Àº À庮 ÇÇÀÓ¹ý, Àڱà ³» ÀåÄ¡(IUD), ÇÇÀÓ ÀÓÇöõÆ® ¹× ÆÐÄ¡¿Í °°Àº ½Å±â¼úÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ·¯ÇÑ Á¦Ç°ÀÇ Çʿ伺Àº »ý½Ä °Ç°­ÀÇ ±Ç¸®, Àα¸ ¾ïÁ¦, °¡Á·°èȹ¿¡ °üÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ¼±ÅÃÀ» ÇÒ ¼ö ÀÖ´Â ¿©¼ºÀÇ ±ÇÇÑ ºÎ¿©¿¡ ´ëÇÑ Àü ¼¼°èÀûÀÎ °ü½É Áõ°¡¿¡ ÈûÀÔ¾î Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÇÇÀÓ¾àÀÇ ¿ëµµ´Â ÀϽÃÀû ¶Ç´Â Àå±âÀû Çʿ信 µû¶ó ´Ù¾çÇÏ°Ô Àû¿ëµÇ¸ç, ÃÖÁ¾ »ç¿ë ¹üÀ§´Â °³ÀÎ ¼ÒºñÀÚºÎÅÍ ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü ¹× Á¶Á÷È­µÈ À¯Åë ä³Î¿¡ À̸£±â±îÁö ´Ù¾çÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023) 484¾ï 3,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 548¾ï 7,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 1,198¾ï 9,000¸¸ ´Þ·¯
CAGR(%) 13.82%

ÇÇÀÓ¾à ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â »ý½Ä °Ç°­ ´ëÃ¥¿¡ ´ëÇÑ Àνİú ¼ö¿ë¼º Áõ°¡, °¡Á·°èȹ¿¡ ´ëÇÑ Á¤ºÎ Áö¿ø Ä·ÆäÀÎ, º¸´Ù È¿À²ÀûÀÌ°í Æí¸®ÇÑ ÇÇÀÓ¹ýÀ» °¡´ÉÇÏ°Ô ÇÏ´Â ±â¼ú ¹ßÀü µîÀÌ ÀÖ½À´Ï´Ù. ÇÇÀÓ¿¡ ´ëÇÑ ¹ÌÃæÁ· ¼ö¿ä°¡ ³ôÀº °³¹ßµµ»ó±¹¿¡¼­ ÇÇÀÓ¿¡ ´ëÇÑ Á¢±Ù¼º È®´ë¿Í ºÎÀÛ¿ëÀÌ ¾ø´Â °³ÀÎ ¸ÂÃãÇü ÇÇÀӾ࿡ ´ëÇÑ ¼±Áø±¹ ¼ö¿ä¿¡ ´ëÀÀÇÏ´Â µ¥ ÀáÀçÀûÀÎ ºñÁî´Ï½º ±âȸ°¡ ÀÖ½À´Ï´Ù. Á¤ºÎ ¹× ºñÁ¤ºÎ±â±¸¿ÍÀÇ Àü·«Àû ÆÄÆ®³Ê½ÊÀ» ÅëÇØ ½ÃÀå Á¢±Ù¼º°ú ħÅõ·ÂÀ» °­È­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±×·¯³ª »çȸÀû, Á¾±³Àû ÀúÇ×, ºÎÀÛ¿ë °¡´É¼º, »ç¿ë¿¡ ´ëÇÑ ¿ÀÇØ, °¢ Áö¿ªÀÇ ±ÔÁ¦ ¹®Á¦ µîÀ¸·Î ÀÎÇØ ½ÃÀå ¼ºÀåÀº ÇѰ迡 Á÷¸éÇØ ÀÖ½À´Ï´Ù.

¿¬±¸°¡ Ȱ¹ßÈ÷ ÁøÇàµÇ°í ÀÖ´Â Çõ½ÅÀûÀÎ ºÐ¾ß·Î´Â ³²¼º¿ë ÇÇÀÓ¾à °³¹ß, ¿©¼ºÀÇ ºÎÀÛ¿ëÀ» ÁÙÀÏ ¼ö ÀÖ´Â ºñÈ£¸£¸ó ÇÇÀÓ¾à, °³ÀÎ ¸ÂÃãÇü ÇÇÀÓ¾à Á¶¾ðÀ» Á¦°øÇÏ´Â µðÁöÅÐ °Ç°­ ¼Ö·ç¼Ç µîÀÌ ÀÖ½À´Ï´Ù. ÇÇÀÓ¾à ½ÃÀåÀº ¿ªµ¿ÀûÀÌ¸ç ¹®È­Àû, »çȸÀû, °æÁ¦Àû ¿äÀο¡ ¸Å¿ì ¹Î°¨ÇÕ´Ï´Ù. ½ÃÀå Çൿ¿¡ ´ëÇÑ ÅëÂû·Â¿¡ µû¸£¸é, ¼ÒºñÀÚ ¼±È£µµ°¡ ÆíÀǼº, ÃÖ¼Ò Ä§½À¼º, Àå±âÀûÀÎ ½Å·Ú¼ºÀ¸·Î À̵¿Çϰí ÀÖÀ¸¸ç, ÀÌ´Â ÀÌ·¯ÇÑ Çõ½Å¿¡ ÅõÀÚÇÏ´Â ±â¾÷¿¡°Ô Å« ÀáÀç·ÂÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. Àü·«Àû Á¦¾ÈÀ¸·Î´Â ÷´Ü ¼Ö·ç¼Ç ¿¬±¸°³¹ß¿¡ ´ëÇÑ ÅõÀÚ, ¼ÒºñÀÚ ±³À° °­È­, ¹®È­Àû À庮°ú ¿ÀÇØ¸¦ ±Øº¹Çϱâ À§ÇÑ ¸¶ÄÉÆÃ Àü·«ÀÇ Á¶Á¤ µîÀÌ ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â ÇÇÀÓ¾à ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® ÆÄ¾Ç

ÇÇÀÓ¾à ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª Àü¹Ý¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ÁÙÀÏ ¼ö ÀÖÀ¸¸ç, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ¼º °Ç°­ ¹× °¡Á·°èȹ¿¡ ´ëÇÑ ÀÎ½Ä Á¦°í
    • ÇÇÀÓ¾à »ç¿ë ¹× Á¦°øÀ» Àå·ÁÇÏ´Â Á¤ºÎÀÇ Áö¿ø ÀÌ´Ï¼ÅÆ¼ºê
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÇÇÀÓ¾à Á¦Ç°À¸·Î ÀÎÇÑ °Ç°­ ¾Ç¿µÇâ
  • ½ÃÀå ±âȸ
    • ±¤¹üÀ§ÇÑ Á¶»ç °³¹ßÀ» ÅëÇÑ Àú·ÅÇÑ ÇÇÀÓ¹ý ¼Ò°³
    • ¿Â¶óÀÎ À¯Åë ä³ÎÀ» ÅëÇÑ ÇÇÀÓ¾àÀÇ °¡¿ë¼º
  • ½ÃÀå °úÁ¦
    • ÇÇÀÓ¾à »ç¿ë¿¡ ´ëÇÑ »çȸÀû ¿ì·Á¿Í Á¦Ç° ¸¶ÄÉÆÃ ¹®Á¦

Portre's Five Forces: ÇÇÀÓ¾à ½ÃÀå °ø·«À» À§ÇÑ Àü·« µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ÇÇÀÓ¾à ½ÃÀå °æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ¸ð»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ÇÇÀÓ¾à ½ÃÀå¿¡¼­ÀÇ ¿ÜºÎ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ÇÇÀÓ¾à ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀû À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ÇÇÀÓ¾à ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

ÇÇÀÓ¾à ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­, ÅëÇÕÀÇ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ÇÇÀÓ¾à ½ÃÀå¿¡¼­°ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ÇÇÀÓ¾à ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀº º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ±¸ºÐÇÏ¿© »ç¿ëÀÚ°¡ Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ½Äº°ÇÒ ¼ö ÀÖµµ·Ï µµ¿ÍÁÝ´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â Á¾ÇÕÀûÀÎ ½ÃÀå ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ¾÷°è ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅ͸¦ Æ÷ÇÔÇÑ ÇöÀç ½ÃÀå ȯ°æ¿¡ ´ëÇÑ »ó¼¼ÇÑ °ËÅä.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀÌ ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ´ÙÀ½°ú °°Àº Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ÇÇÀÓ¾à ½ÃÀå : Á¦Ç°º°

  • µð¹ÙÀ̽º
    • Äܵ¼
    • ´ÙÀ̾îÇÁ·¥
    • Àڱó» ÇÇÀÓ ±â±¸
      • ±¸¸® IUD
      • È£¸£¸ó¼º IUD
    • ÇÇÇÏ ÀÓÇöõÆ®
    • Áú¸µ
  • ¾à¹°
    • ÁÖ»çÁ¦
    • °æ±¸ ÇÇÀÓ¾à Á¤Á¦
    • °æÇÇ ÇÇÀÓ¾à ÆÐÄ¡

Á¦7Àå ÇÇÀÓ¾à ½ÃÀå : ¼ºº°

  • ¿©¼º ÇÇÀÓ¾à
  • ³²¼º ÇÇÀÓ¾à

Á¦8Àå ÇÇÀÓ¾à ½ÃÀå : ¹æ¹ýº°

  • Barrier
  • Harmonal

Á¦9Àå ÇÇÀÓ¾à ½ÃÀå : À¯Åë¿øº°

  • üÀÎ ¾à±¹
  • Ŭ¸®´Ð
  • Á¤ºÎ ³×Æ®¿öÅ©
  • º´¿ø ¾à±¹
  • µ¶¸³ ¾à±¹
  • ¿Â¶óÀÎ Ç÷§Æû

Á¦10Àå ¾Æ¸Þ¸®Ä«ÀÇ ÇÇÀÓ¾à ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦11Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ÇÇÀÓ¾à ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦12Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ÇÇÀÓ¾à ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023³â
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®

±â¾÷ ¸®½ºÆ®

  • Abbvie Inc.
  • Acme Generics Pvt. Ltd.
  • Afaxys, Inc.
  • Agile Therapeutics, Inc.
  • Amneal Pharmaceuticals LLC
  • ASKA Pharmaceutical Co., Ltd.
  • Aurobindo Pharma Limited
  • Bayer AG
  • Church & Dwight Co., Inc.
  • HLL Lifecare Limited
  • Insud Pharma, S.L.
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Mayne Pharma Group Limited
  • Merck & Co., Inc.
  • Mithra Pharmaceuticals S.A.
  • Okamoto Industries, Inc.
  • Organon & Co.
  • Perrigo Company plc
  • Pfizer Inc.
  • Piramal Pharma Ltd.
  • Reckitt Benckiser Group plc
  • RITEX GMBH
  • Sanofi S.A.
  • Say It With A Condom, LLC.
  • Syzygy Healthcare Solutions LLC
  • Teva Pharmaceutical Industries Ltd.
  • TherapeuticsMD, Inc.
  • TTK Healthcare Limited
  • Veru Inc.
  • Viatris Inc.
LSH

The Contraceptive Market was valued at USD 48.43 billion in 2023, expected to reach USD 54.87 billion in 2024, and is projected to grow at a CAGR of 13.82%, to USD 119.89 billion by 2030.

The contraceptive market encompasses a range of products and services aimed at preventing pregnancy, managing reproductive health, and addressing sexually transmitted infections. Its scope includes hormonal methods like pills and injectable contraceptives, barrier methods such as condoms and diaphragms, intrauterine devices (IUDs), and emerging technologies like contraceptive implants and patches. The necessity for such products is driven by the increasing global focus on reproductive health rights, population control, and the empowerment of women to make informed choices regarding family planning. The application of contraceptives is widespread, catering to both temporary and long-term needs of users, with end-use scopes stretching from individual consumers to healthcare providers and institutional distribution channels.

KEY MARKET STATISTICS
Base Year [2023] USD 48.43 billion
Estimated Year [2024] USD 54.87 billion
Forecast Year [2030] USD 119.89 billion
CAGR (%) 13.82%

Key growth factors influencing the contraceptive market include the rising awareness and acceptance of reproductive health measures, supportive governmental campaigns for family planning, and technological advancements leading to more efficient and convenient contraceptive methods. There are potential opportunities in expanding access in developing regions where unmet needs for contraceptives are high, as well as addressing the demand in developed countries for more personalized and side-effect-free options. Strategic partnerships with governmental and non-governmental organizations can enhance market reach and penetration. However, market growth faces limitations from societal and religious resistances, potential side effects and misconceptions about contraceptive use, and regulatory challenges in different regions.

Innovative areas ripe for research include the development of male contraceptives, non-hormonal options that reduce side effects for women, and digital health solutions that offer personalized contraceptive advice. The contraceptive market is dynamic and highly sensitive to cultural, social, and economic factors. Insights into market behavior suggest a consumer preference shift towards convenience, minimal invasiveness, and long-term reliability, indicating significant potential for companies investing in these innovations. Strategic recommendations include investing in R&D for cutting-edge solutions, enhancing consumer education, and tailoring marketing strategies to overcome cultural barriers and misconceptions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Contraceptive Market

The Contraceptive Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increased awareness regarding sexual health and family planning
    • Supportive government initiatives to encourage use and provision of contraceptive pills
  • Market Restraints
    • Adverse health impacts of contraceptive products
  • Market Opportunities
    • Introduction of affordable contraceptive methods with extensive R&D
    • Availability of contraceptives through online distribution channels
  • Market Challenges
    • Social concerns regarding contraceptive usage and issues with product marketing

Porter's Five Forces: A Strategic Tool for Navigating the Contraceptive Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Contraceptive Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Contraceptive Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Contraceptive Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Contraceptive Market

A detailed market share analysis in the Contraceptive Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Contraceptive Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Contraceptive Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Contraceptive Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Acme Generics Pvt. Ltd., Afaxys, Inc., Agile Therapeutics, Inc., Amneal Pharmaceuticals LLC, ASKA Pharmaceutical Co., Ltd., Aurobindo Pharma Limited, Bayer AG, Church & Dwight Co., Inc., HLL Lifecare Limited, Insud Pharma, S.L., Johnson & Johnson Services, Inc., Lupin Limited, Mayne Pharma Group Limited, Merck & Co., Inc., Mithra Pharmaceuticals S.A., Okamoto Industries, Inc., Organon & Co., Perrigo Company plc, Pfizer Inc., Piramal Pharma Ltd., Reckitt Benckiser Group plc, RITEX GMBH, Sanofi S.A., Say It With A Condom, LLC., Syzygy Healthcare Solutions LLC, Teva Pharmaceutical Industries Ltd., TherapeuticsMD, Inc., TTK Healthcare Limited, Veru Inc., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Contraceptive Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Devices and Drugs. The Devices is further studied across Condoms, Diaphragm, IUDs, Subdermal Implants, and Vaginal Rings. The IUDs is further studied across Copper IUDs and Hormonal IUDs. The Drugs is further studied across Injectables, Oral Contraceptive Pills, and Transdermal Contraceptive Patch.
  • Based on Gender, market is studied across Female Contraceptive and Male Contraceptive.
  • Based on Method, market is studied across Barrier and Harmonal.
  • Based on Distribution, market is studied across Chain Pharmacy, Clinics, Government Network, Hospital Pharmacy, Independent Pharmacy, and Online Platform.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increased awareness regarding sexual health and family planning
      • 5.1.1.2. Supportive government initiatives to encourage use and provision of contraceptive pills
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse health impacts of contraceptive products
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of affordable contraceptive methods with extensive R&D
      • 5.1.3.2. Availability of contraceptives through online distribution channels
    • 5.1.4. Challenges
      • 5.1.4.1. Social concerns regarding contraceptive usage and issues with product marketing
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: High inclination toward contraceptive drugs due to their ease of use and non-invasiveness
    • 5.2.2. Gender: Significant adoption of female contraceptives due to availability of a wide range of products
    • 5.2.3. Method: Rising preference for barrier methods of contraception that provide a physical and chemical barrier during sexual activities
    • 5.2.4. Distribution Channel: Enhanced product distribution through online pharmacies due to their 24/7 services
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Contraceptive Market, by Product

  • 6.1. Introduction
  • 6.2. Devices
    • 6.2.1. Condoms
    • 6.2.2. Diaphragm
    • 6.2.3. IUDs
      • 6.2.3.1. Copper IUDs
      • 6.2.3.2. Hormonal IUDs
    • 6.2.4. Subdermal Implants
    • 6.2.5. Vaginal Rings
  • 6.3. Drugs
    • 6.3.1. Injectables
    • 6.3.2. Oral Contraceptive Pills
    • 6.3.3. Transdermal Contraceptive Patch

7. Contraceptive Market, by Gender

  • 7.1. Introduction
  • 7.2. Female Contraceptive
  • 7.3. Male Contraceptive

8. Contraceptive Market, by Method

  • 8.1. Introduction
  • 8.2. Barrier
  • 8.3. Harmonal

9. Contraceptive Market, by Distribution

  • 9.1. Introduction
  • 9.2. Chain Pharmacy
  • 9.3. Clinics
  • 9.4. Government Network
  • 9.5. Hospital Pharmacy
  • 9.6. Independent Pharmacy
  • 9.7. Online Platform

10. Americas Contraceptive Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Contraceptive Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Contraceptive Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Richmond Biotech Company to buy Contraceptive biz for USD 100 Million
    • 13.3.2. UK Launches First Trial of Hormone-free Male Birth Control pill
    • 13.3.3. Aditxt Acquires Phexxi Contraceptive Gel-Maker Evofem for USD 100 million
    • 13.3.4. Dare Bioscience Launches Phase III Hormone-free Contraceptive Trial
    • 13.3.5. Lupin Launches Turqoz (Norgestrel and Ethinyl Estradiol) Tablets USP in the United States
    • 13.3.6. Bayer and CrossBay Medical to Develop Novel Intrauterine System Inserter
    • 13.3.7. Xiromed LLC Announces Launch of EnilloRing in the United States
    • 13.3.8. Bayer Invests in USD 267.2 Million new Production Facility in Finland to Accelerate Global Access to Modern Contraception
    • 13.3.9. NIH Center Grant Bolsters Male Contraceptive Research
    • 13.3.10. Gates Foundation, Children's Investment Fund Foundation, Pfizer and BD Company Expand Partnership for Greater Access to Injectable Contraceptive for Women
    • 13.3.11. Perrigo Announces U.S. FDA Approval for Opill OTC Daily Oral Contraceptive
    • 13.3.12. FDA Approves First Nonprescription Daily Oral Contraceptive
    • 13.3.13. Sirona Acquires India's First Vegan Condom Brand Bleu

Companies Mentioned

  • 1. Abbvie Inc.
  • 2. Acme Generics Pvt. Ltd.
  • 3. Afaxys, Inc.
  • 4. Agile Therapeutics, Inc.
  • 5. Amneal Pharmaceuticals LLC
  • 6. ASKA Pharmaceutical Co., Ltd.
  • 7. Aurobindo Pharma Limited
  • 8. Bayer AG
  • 9. Church & Dwight Co., Inc.
  • 10. HLL Lifecare Limited
  • 11. Insud Pharma, S.L.
  • 12. Johnson & Johnson Services, Inc.
  • 13. Lupin Limited
  • 14. Mayne Pharma Group Limited
  • 15. Merck & Co., Inc.
  • 16. Mithra Pharmaceuticals S.A.
  • 17. Okamoto Industries, Inc.
  • 18. Organon & Co.
  • 19. Perrigo Company plc
  • 20. Pfizer Inc.
  • 21. Piramal Pharma Ltd.
  • 22. Reckitt Benckiser Group plc
  • 23. RITEX GMBH
  • 24. Sanofi S.A.
  • 25. Say It With A Condom, LLC.
  • 26. Syzygy Healthcare Solutions LLC
  • 27. Teva Pharmaceutical Industries Ltd.
  • 28. TherapeuticsMD, Inc.
  • 29. TTK Healthcare Limited
  • 30. Veru Inc.
  • 31. Viatris Inc.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦